TFS Capital’s Aratana Therapeutics, Inc. PETX Stock Holding History

TFS Capital’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-53,001	Closed	-$381K	–	950
2016 Q4	$381K	Sell	53,001 -139,847	-73%	-$1.13M	0.1%	352
2016 Q3	$1.8M	Buy	192,848 +178,357	+1,231%	+$1.48M	0.43%	29
2016 Q2	$92K	Sell	14,491 -38,027	-72%	-$245K	0.02%	866
2016 Q1	$290K	Sell	52,518 -19,748	-27%	-$74.2K	0.04%	656
2015 Q4	$403K	Buy	+72,266	New	+$478K	0.04%	461
2014 Q3	–	Sell	-48,883	Closed	-$763K	–	1317
2014 Q2	$763K	Buy	48,883 +31,916	+188%	+$452K	0.06%	500
2014 Q1	$315K	Buy	+16,967	New	+$340K	0.02%	992

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

TFS Capital's PETX Position: Q1 2017 in Review

TFS Capital sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2017, closing a stake of 53,001 shares — an estimated $381K sold.

TFS Capital first reported a position in PETX in Q1 2014 and held it in 7 quarters. The position peaked at $1.8M in Q3 2016. 98 funds tracked by Wall St. Rank hold PETX as of Q1 2017.

TFS Capital reported no remaining Aratana Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 53,001 Aratana Therapeutics, Inc. shares in Q1 2017, an estimated $381K.
TFS Capital first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 7 quarters.
TFS Capital's Aratana Therapeutics, Inc. position peaked at $1.8M in Q3 2016.
98 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.